Dr. LM Larratt


Department of Medicine

Division of Hematology (DoM)
    Contact details are for academic matters only.

About Me

Personal Statement

Through basic and clinical research, we’ve made many advances in the treatment of blood cell disease that increase patient survival. We can also increase patient quality of life through education and training opportunities for health care staff on new technologies and treatments, and programs to advance patients’ care and education.

Dr. Loree Larratt followed her training in internal medicine and clinical hematology at the University of Toronto with fellowships in transplantation and leukemia at Princess Margaret Hospital, also in Toronto. She came to Edmonton in 1987 to join the Department of Medicine and the University of Alberta Hospital as a clinical hematologist. She consults in the Department of Medical Oncology at the Cross Cancer Institute.

Leadership and Collaborations

Dr. Larratt is on the Medical and Scientific Advisory Committee of the Aplastic Anemia & Myelodysplasia Association of Canada. She is a member of the Canadian Paroxysmal nocturnal hemoglobinuria (PNH) Network and the Canadian Hematology Society.


Dr. Larratt conducts research and clinical trials on a number of blood diseases and disorders including acute and chronic leukemia, myeloproliferative disorders, aplastic anemia and paroxysmal nocturnal hemoglobinuria (PNH) and Idiopathic thrombocytopenic purpura (ITP). She is also involved in clinical trials for therapeutics to treat blood disorders. One clinical trial she participated in led to Canadian approval for a drug used to treat PNH, a rare disorder. She has authored or co-authored many articles resulting from her clinical research in leading scientific journals including Blood, European Journal of Hematology, Lancet Oncology, Leukemia and the Canadian Journal of Kidney Health on the topic of blood diseases and related disorders.

Research Keywords

chemotherapy, Phase 4 trial to study safety of romiplostim, placebo controlled trial with revlimid, studying safety of attenuated vaccine vs placebo, transplantation